US Drug Manufacturers Poised for Windfall From Trump’s Tariffs

Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump’s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.

Those lesser-known firms, such as Lonza Group AG, Thermo Fisher Scientific Inc. and Catalent Inc., help big pharma companies with their complex supply chains, from filling syringes and producing pills all the way to manufacturing complicated biologic drugs from scratch.

So as the health-care industry scrambles to minimize the impact of tariffs, conversations between drugmakers and the companies that can quickly ramp production in the US have taken ...